You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/128576
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOliveira, L.-
dc.contributor.authorCosta, A. C.-
dc.contributor.authorNoronha-Matos, J. B.-
dc.contributor.authorSilva, I.-
dc.contributor.authorCavalcante, Walter Luís Garrido-
dc.contributor.authorTimoteo, M. A.-
dc.contributor.authorCorrado, A. P.-
dc.contributor.authorDal Belo, C. A.-
dc.contributor.authorAmbiel, C. R.-
dc.contributor.authorAlves-do-Prado, W.-
dc.contributor.authorCorreia-de-Sa, P.-
dc.date.accessioned2015-10-21T13:11:08Z-
dc.date.accessioned2016-10-25T20:59:56Z-
dc.date.available2015-10-21T13:11:08Z-
dc.date.available2016-10-25T20:59:56Z-
dc.date.issued2015-02-01-
dc.identifierhttp://www.sciencedirect.com/science/article/pii/S0028390814003116-
dc.identifier.citationNeuropharmacology, v. 89, p. 64-76, 2015.-
dc.identifier.issn0028-3908-
dc.identifier.urihttp://hdl.handle.net/11449/128576-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/128576-
dc.description.abstractThe mechanisms underlying improvement of neuromuscular transmission deficits by glucocorticoids are still a matter of debate despite these compounds have been used for decades in the treatment of autoimmune myasthenic syndromes. Besides their immunosuppressive action, corticosteroids may directly facilitate transmitter release during high-frequency motor nerve activity. This effect coincides with the predominant adenosine A(2A) receptor tonus, which coordinates the interplay with other receptors (e.g. muscarinic) on motor nerve endings to sustain acetylcholine (ACh) release that is required to overcome tetanic neuromuscular depression in myasthenics. Using myographic recordings, measurements of evoked [H-3]ACh release and real-time video microscopy with the FM4-64 fluorescent dye, results show that tonic activation of facilitatory A(2A) receptors by endogenous adenosine accumulated during 50 Hz bursts delivered to the rat phrenic nerve is essential for methylprednisolone (03 mM)-induced transmitter release facilitation, because its effect was prevented by the A(2A) receptor antagonist, ZM 241385 (10 nM). Concurrent activation of the positive feedback loop operated by pirenzepine-sensitive muscarinic M-1 autoreceptors may also play a role, whereas the corticosteroid action is restrained by the activation of co-expressed inhibitory M-2 and Al receptors blocked by methoctramine (0.1 mu M) and DPCPX (2.5 nM), respectively. Inhibition of FM4-64 loading (endocytosis) by methylprednisolone following a brief tetanic stimulus (50 Hz for 5 s) suggests that it may negatively modulate synaptic vesicle turnover, thus increasing the release probability of newly recycled vesicles. Interestingly, bulk endocytosis was rehabilitated when methylprednisolone was co-applied with ZM241385. Data suggest that amplification of neuromuscular transmission by methylprednisolone may involve activation of presynaptic facilitatory adenosine A(2A) receptors by endogenous adenosine leading to synaptic vesicle redistribution. (C) 2014 Elsevier Ltd. All rights reserved.en
dc.description.sponsorshipFundação para a Ciência e a Tecnologia (FCT)-
dc.description.sponsorshipFoundation of Research and Development of the State University of Maringa (FADEC-UEM)-
dc.format.extent64-76-
dc.language.isoeng-
dc.publisherElsevier B.V.-
dc.sourceWeb of Science-
dc.subjectNeuromuscular junctionen
dc.subjectSynaptic vesicle recyclingen
dc.subjectAcetylcholine releaseen
dc.subjectGlucocorticoidsen
dc.subjectAdenosine receptorsen
dc.subjectMuscarinic receptorsen
dc.titleAmplification of neuromuscular transmission by methylprednisolone involves activation of presynaptic facilitatory adenosine A(2A) receptors and redistribution of synaptic vesiclesen
dc.typeoutro-
dc.contributor.institutionUniv Porto-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.contributor.institutionUniversidade Federal do Pampa (UNIPAMPA)-
dc.contributor.institutionUniversidade Estadual de Maringá (UEM)-
dc.description.affiliationUniv Porto, UMIB, Lab Farmacol &Neurobiol, P-4050313 Oporto, Portugal-
dc.description.affiliationUniv Porto, Ctr Drug Discovery &Innovat Med MedInUP, P-4050313 Oporto, Portugal-
dc.description.affiliationUNESP, Inst Biociencias, Botucatu, SP, Brazil-
dc.description.affiliationUniv Sao Paulo, Fac Med Ribeirao Preto, Dept Farmacol, Sao Gabriel, Rio Grande Do S, Brazil-
dc.description.affiliationUniv Fed Pampa, Sao Gabriel, Rio Grande Do S, Brazil-
dc.description.affiliationUniv Estadual Maringa, Dept Ciencias Fisiol, Maringa, Parana, Brazil-
dc.description.affiliationUniv Estadual Maringa, Dept Farmacol &Terapeut, Maringa, Parana, Brazil-
dc.description.affiliationUnespUNESP, Departamento de Física e Biofísica, Inst Biociencias, Botucatu, SP, Brazil-
dc.description.sponsorshipIdFCT: Pest/OE/U10215/2014-
dc.description.sponsorshipIdFCT: SRFH/BD/68584/2010-
dc.description.sponsorshipIdFCT: SFRH/BD/88855/2012-
dc.identifier.doihttp://dx.doi.org/10.1016/j.neuropharm.2014.09.004-
dc.identifier.wosWOS:000347597600007-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofNeuropharmacology-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.